GleamWall
中文EN

ABCL AbCellera Biologics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1703057 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY92.1%
TTM net income YoY13.6%
TTM EPS YoY15.8%
Revenue 3-yr CAGR10.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-298.0%
Net margin-218.5%
FCF margin-48.4%
EBITDA margin-264.0%

Returns

ROE-14.6%
ROA-10.4%
ROIC (approx.)-18.2%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets29.2%
Debt / equity0.00x
Current ratio12.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue25.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$75.13M$28.83M$38.02M$485.42M$375.20M
R&D expense$186.83M$167.26M$175.66M$107.88M$62.06M
SG&A expense$83.23M$85.49M$75.18M$55.48M$41.85M
Operating income-$217.10M-$314.77M-$237.21M$216.51M$204.41M
Pretax income-$177.59M-$200.40M-$174.03M$239.10M$219.15M
Income tax-$31.18M-$37.54M-$27.63M$80.58M$65.69M
Net income-$146.41M-$162.86M-$146.40M$158.52M$153.46M
EBITDA-$198.66M-$302.23M-$224.45M$225.46M$218.86M
EPS (basic)-0.49-0.55-0.510.560.56
EPS (diluted)-0.49-0.55-0.510.500.48
Weighted avg. shares (diluted)298.71M294.33M289.17M314.83M318.29M
Balance sheet
Cash & equivalents$128.51M$156.32M$158.32M$411.54M$501.14M
Receivables$39.41M$31.98M$0——
Inventory$6.34M$0———
Current assets$728.23M$751.37M$871.99M$1.03B$929.80M
PP&E, net———$217.25M$111.62M
Goodwill$47.81M$47.81M$47.81M$47.81M$47.81M
Intangibles$38.38M$42.11M$120.42M$131.50M$148.39M
Total assets$1.36B$1.36B$1.49B$1.54B$1.32B
Current liabilities$64.31M$76.61M$119.01M$118.32M$120.68M
Total liabilities$390.05M$304.47M$335.78M$307.63M$292.84M
Shareholders' equity$966.90M$1.06B$1.15B$1.23B$1.03B
Shares outstanding300.60M295.76M290.82M286.85M283.26M
Cash flow statement
Operating cash flow-$131.29M-$108.56M-$43.88M$277.36M$244.58M
Capital expenditure$42.77M$78.40M$76.95M$70.66M$58.45M
Free cash flow-$174.07M-$186.95M-$120.82M$206.70M$186.13M
Investing cash flow$87.75M$121.41M-$221.11M-$352.62M-$332.25M
Financing cash flow$14.08M$12.77M$10.36M-$1.63M-$3.89M
Depreciation & amortization$18.44M$12.54M$12.76M$8.95M$14.45M
Stock-based compensation$55.79M$67.58M$64.18M$49.48M$30.65M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.